Table 2 E-Cadherin immunostaining and tumor phenotype
From: E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors
| Â | Â | Â | E-Cadherin immunostaining | ||||
|---|---|---|---|---|---|---|---|
n | negative (%) | weak (%) | moderate (%) | strong (%) | P | ||
Invasive breast carcinoma of no special type | all cancers | 757 | 1.1 | 2.6 | 3.6 | 92.7 | Â |
pT1 | 392 | 1.3 | 2.6 | 2.8 | 93.4 | 0.6066 | |
pT2 | 276 | 0.7 | 2.9 | 3.6 | 92.8 | Â | |
pT3–4 | 60 | 1.7 | 3.3 | 8.3 | 86.7 |  | |
Grade 1 | 111 | 0.0 | 0.0 | 0.0 | 100.0 | 0.0009 | |
Grade 2 | 393 | 1.8 | 3.6 | 3.6 | 91.1 | Â | |
Grade 3 | 252 | 0.4 | 2.4 | 5.2 | 92.1 | Â | |
pN0 | 360 | 1.1 | 1.9 | 3.3 | 93.6 | 0.5155 | |
pN ≥ 1 | 247 | 0.8 | 3.6 | 4.5 | 91.1 |  | |
pM0 | 174 | 1.1 | 2.3 | 2.3 | 94.3 | 0.1374 | |
pM1 | 80 | 0.0 | 3.8 | 7.5 | 88.8 | Â | |
HER2 negative | 563 | 1.1 | 2.5 | 4.4 | 92.0 | 0.2221 | |
HER2 positive | 77 | 0.0 | 1.3 | 1.3 | 97.4 | Â | |
ER negative | 133 | 1.5 | 3.8 | 6.8 | 88.0 | 0.1269 | |
ER positve | 475 | 0.8 | 1.7 | 3.2 | 94.3 | Â | |
PR negative | 250 | 1.2 | 2.0 | 5.2 | 91.6 | 0.7046 | |
PR positive | 388 | 1.0 | 2.3 | 3.4 | 93.3 | Â | |
not Triple negative | 499 | 0.8 | 1.6 | 3.2 | 94.4 | 0.0336 | |
Triple negative | 93 | 2.2 | 4.3 | 8.6 | 84.9 | Â | |
Lobular carcinoma of the breast | all cancers | 93 | 65.6 | 9.7 | 9.7 | 15.1 | Â |
pT1 | 40 | 72.5 | 10.0 | 5.0 | 12.5 | 0.7552 | |
pT2 | 35 | 62.9 | 8.6 | 11.4 | 17.1 | Â | |
pT3–4 | 16 | 56.3 | 6.3 | 18.8 | 18.8 |  | |
Grade 1 | 4 | 50.0 | 25.0 | 0.0 | 25.0 | 0.3431 | |
Grade 2 | 76 | 67.1 | 10.5 | 10.5 | 11.8 | Â | |
Grade 3 | 13 | 61.5 | 0.0 | 7.7 | 30.8 | Â | |
pN0 | 54 | 64.8 | 9.3 | 11.1 | 14.8 | 0.5989 | |
pN ≥ 1 | 11 | 70.0 | 3.3 | 6.7 | 20.0 |  | |
pM0 | 21 | 71.4 | 0.0 | 9.5 | 19.0 | 0.9970 | |
pM1 | 11 | 72.7 | 0.0 | 9.1 | 18.2 | Â | |
HER2 negative | 65 | 69.2 | 7.7 | 12.3 | 10.8 | 0.8664 | |
HER2 positive | 1 | 100.0 | 0.0 | 0.0 | 0.0 | Â | |
ER negative | 8 | 62.5 | 0.0 | 37.5 | 0.0 | 0.0909 | |
ER positve | 47 | 70.2 | 8.5 | 8.5 | 12.8 | Â | |
PR negative | 30 | 73.3 | 0.0 | 16.7 | 10.0 | 0.0672 | |
PR positive | 34 | 67.6 | 11.8 | 5.9 | 14.7 | Â | |
not Triple negative | 47 | 70.2 | 8.5 | 8.5 | 12.8 | 0.0454 | |
Triple negative | 5 | 40.0 | 0.0 | 60.0 | 0.0 | Â | |
Colorectal cancers | all cancers | 1570 | 0.5 | 5.5 | 9.7 | 84.3 | Â |
pT1 | 63 | 0.0 | 6.3 | 4.8 | 88.9 | 0.0047 | |
pT2 | 313 | 0.0 | 4.8 | 5.4 | 89.8 | Â | |
pT3 | 859 | 0.7 | 5.2 | 9.8 | 84.3 | Â | |
pT4 | 321 | 0.6 | 6.9 | 14.3 | 78.2 | Â | |
pN0 | 808 | 0.4 | 4.7 | 5.9 | 89.0 | < 0.0001 | |
pN+ | 732 | 0.7 | 6.4 | 13.8 | 79.1 | Â | |
V0 | 1135 | 0.3 | 5.2 | 7.8 | 86.8 | < 0.0001 | |
V+ | 396 | 1.0 | 6.8 | 15.2 | 77.0 | Â | |
L0 | 595 | 0.3 | 5.2 | 5.5 | 88.9 | < 0.0001 | |
L1 | 922 | 0.7 | 6.0 | 12.5 | 80.9 | Â | |
left | 1142 | 0.4 | 6.0 | 9.5 | 84.1 | 0.4828 | |
right | 422 | 0.7 | 4.3 | 10.2 | 84.8 | Â | |
microsatellite instable | 80 | 1.3 | 10.0 | 7.5 | 81.3 | 0.1616 | |
microsatellite stable | 1096 | 0.3 | 4.6 | 8.1 | 87.0 | Â | |
RAS mutation | 328 | 0.9 | 7.3 | 8.5 | 83.2 | 0.1609 | |
RAS wild type | 420 | 0.0 | 7.1 | 9.5 | 83.3 | Â | |
BRAF V600E mutation | 18 | 0.0 | 16.7 | 11.1 | 72.2 | 0.3486 | |
BRAF wild type | 122 | 0.8 | 4.9 | 8.2 | 86.1 | Â | |
Clear cell renal cell carcinoma | all cancers | 569 | 51.1 | 25.1 | 14.2 | 9.5 | Â |
ISUP 1 | 179 | 62.0 | 20.7 | 11.7 | 5.6 | < 0.0001 | |
ISUP 2 | 185 | 45.9 | 30.8 | 14.6 | 8.6 | Â | |
ISUP 3 | 163 | 42.3 | 27.6 | 16.6 | 13.5 | Â | |
ISUP 4 | 34 | 70.6 | 11.8 | 11.8 | 5.9 | Â | |
Fuhrmann 1 | 25 | 72.0 | 20.0 | 8.0 | 0.0 | 0.1532 | |
Fuhrmann 2 | 334 | 51.5 | 26.3 | 13.8 | 8.4 | Â | |
Fuhrmann 3 | 169 | 45.6 | 25.4 | 16.6 | 12.4 | Â | |
Fuhrmann 4 | 40 | 60.0 | 17.5 | 12.5 | 10.0 | Â | |
Thoenes 1 | 194 | 61.3 | 22.7 | 10.8 | 5.2 | 0.0036 | |
Thoenes 2 | 318 | 44.0 | 28.0 | 16.7 | 11.3 | Â | |
Thoenes 3 | 56 | 57.1 | 17.9 | 12.5 | 12.5 | Â | |
UICC 1 | 238 | 50.8 | 26.1 | 15.5 | 7.6 | 0.1201 | |
UICC 2 | 27 | 51.9 | 25.9 | 7.4 | 14.8 | Â | |
UICC 3 | 76 | 31.6 | 36.8 | 15.8 | 15.8 | Â | |
UICC 4 | 62 | 53.2 | 24.2 | 12.9 | 9.7 | Â | |
pT1 | 319 | 52.4 | 23.8 | 16.0 | 7.8 | 0.0276 | |
pT2 | 60 | 66.7 | 16.7 | 6.7 | 10.0 | Â | |
pT3–4 | 185 | 44.3 | 30.3 | 13.5 | 11.9 |  | |
pN0 | 100 | 50.0 | 25.0 | 12.0 | 13.0 | 0.4847 | |
pN ≥ 1 | 14 | 28.6 | 35.7 | 14.3 | 21.4 |  | |
pM0 | 86 | 44.2 | 32.6 | 14.0 | 9.3 | 0.5788 | |
pM ≥ 1 | 64 | 54.7 | 23.4 | 12.5 | 9.4 |  | |
Papillary renal cell carcinoma | all cancers | 131 | 59.0 | 25.9 | 5.8 | 9.3 | Â |
ISUP 1 | 26 | 69.2 | 23.1 | 3.8 | 3.8 | 0.0207 | |
ISUP 2 | 65 | 52.3 | 29.2 | 6.2 | 12.3 | Â | |
ISUP 3 | 46 | 63.0 | 23.9 | 4.3 | 8.7 | Â | |
ISUP 4 | 1 | 0.0 | 0.0 | 100.0 | 0.0 | Â | |
Fuhrmann 1 | 1 | 100.0 | 0.0 | 0.0 | 0.0 | 0.7761 | |
Fuhrmann 2 | 92 | 58.7 | 27.2 | 4.3 | 9.8 | Â | |
Fuhrmann 3 | 42 | 57.1 | 26.2 | 7.1 | 9.5 | Â | |
Fuhrmann 4 | 3 | 66.7 | 0.0 | 33.3 | 0.0 | Â | |
Thoenes 1 | 33 | 63.6 | 30.3 | 6.1 | 0.0 | 0.018 | |
Thoenes 2 | 96 | 56.3 | 27.1 | 4.2 | 12.5 | Â | |
Thoenes 3 | 9 | 66.7 | 0.0 | 22.2 | 11.1 | Â | |
UICC 1 | 77 | 54.5 | 31.2 | 5.2 | 9.1 | 0.0067 | |
UICC 2 | 10 | 100.0 | 0.0 | 0.0 | 0.0 | Â | |
UICC 3 | 3 | 33.3 | 33.3 | 33.3 | 0.0 | Â | |
UICC 4 | 9 | 55.6 | 0.0 | 11.1 | 33.3 | Â | |
pT1 | 98 | 56.1 | 31.6 | 4.1 | 8.2 | 0.0424 | |
pT2 | 26 | 76.9 | 11.5 | 3.8 | 7.7 | Â | |
pT3–4 | 10 | 40.0 | 10.0 | 20.0 | 30.0 |  | |
pN0 | 14 | 50.0 | 42.9 | 0.0 | 7.1 | 0.0368 | |
pN ≥ 1 | 7 | 57.1 | 0.0 | 14.3 | 28.6 |  | |
pM0 | 23 | 60.9 | 26.1 | 4.3 | 8.7 | 0.2792 | |
pM ≥ 1 | 5 | 60.0 | 0.0 | 20.0 | 20.0 |  | |